Top 5 Drug Type | Count |
---|---|
Small molecule drug | 7 |
Unknown | 1 |
Fusion protein | 1 |
Target |
Mechanism KLKB1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date03 Dec 2020 |
Target |
Mechanism PNP inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date31 Mar 2017 |
Target |
Mechanism neuraminidase inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date13 Jan 2010 |
Start Date24 Oct 2023 |
Sponsor / Collaborator |
Start Date18 Jan 2023 |
Sponsor / Collaborator |
Start Date25 Oct 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Peramivir ( neuraminidase ) | Influenza, Human More | Approved |
Berotralstat Hydrochloride ( KLKB1 ) | Hereditary Angioedema More | Approved |
BCX-9930 ( CFD ) | Hemoglobinuria, Paroxysmal More | Phase 2 |
Galidesivir ( RdRp ) | Yellow Fever More | Phase 2 |
BCX10013 ( CFD ) | - | Phase 1 |